Try GOLD - Free
APAC Vaccine Powerhouses Flex Capacity & Quality Muscle
BioSpectrum Asia
|BioSpectrum Asia May 2025
Asia is the epicentre of global vaccine manufacturing, with India and China together supplying over a billion doses annually. Now, emerging players like South Korea, Singapore, and Australia are stepping up, investing in next-gen platforms and expanding capacity to meet global demand. Let's map the manufacturing footprint of Asia's leading vaccine manufacturers, tracking their current capacity, expansion plans, and the strategic shifts that are transforming the region into a global vaccine production hub.
Asia-Pacific is driving a transformation in the global vaccine supply landscape. According to the WHO Vaccine Report 2024, the WHO South-East Asia region now self-supplies 87 per cent of its vaccines—thanks largely to India, which accounts for 84 per cent of the doses procured in the region and produces 99 per cent of its requirements. Similarly, in the Western Pacific region, China supplies 54 per cent of vaccines and meets 90 per cent of its domestic demand. Manufacturers affiliated with the Developing Countries Vaccine Manufacturers Network (DCVMN) accounted for 54 per cent of global vaccine volumes sold in 2023, further emphasising the role of emerging economies in shaping vaccine access. Together, these two countries are not only meeting regional needs but are scaling up rapidly, with production capacities growing by 15—20 per cent annually. At the same time, Asia as a whole manufacturing base is broadening. The number of companies producing between 10 and 100 million doses annually has jumped from 28 in 2019 to 42 in 2023, with half of this growth coming from China.
While India and China remain the undisputed leaders in vaccine manufacturing, other countries in the Asia-Pacific region are stepping up. South Korea has carved out an impressive niche playing a key role in the global COVAX initiative by supplying vaccines to lower-income countries. Japan and Singapore have focused on high-value, specialised vaccines, with Japanese manufacturers particularly strong in regulated markets like North America and Europe. APAC has a diverse manufacturing ecosystem, while private companies dominate in India and China, government-run manufacturers play a vital role in countries like Thailand, the Philippines, Indonesia, and Vietnam.
This story is from the BioSpectrum Asia May 2025 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
Waters launches charge detection mass spectrometry technology
US-based Waters Corporation has unveiled the Waters Xevo Charge Detection Mass Spectrometer (CDMS), delivering unmatched measurement and characterisation for the broadest range of mega-mass biomolecules central to next-generation therapeutics and structural biology.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Chulalongkorn University launches Thailand's first master's programme in Nurse Anesthesia
The Faculty of Nursing, Chulalongkorn University, has officially launched the \"Master of Nursing Science Programme in Nurse Anesthesia\" - the first of its kind in Thailand.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
WHO strengthens coordination for NTD programmes and supply chain delivery
The World Health Organization (WHO), together with health ministries, pharmaceutical donours, implementing partners and technical support platforms, is strengthening coordination for neglected tropical disease (NTD) programmes and supply chain delivery, through three major back-to-back meetings in Geneva.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
All-in-one coronavirus vaccines to save millions in future pandemics
A new study reveals that vaccines designed to protect against a wide range of coronaviruses could dramatically reduce deaths and economic disruption and limit the need for lockdowns in the event of another global coronavirus pandemic.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
NTU in Singapore introduces Master of Science course in Chinese Medicine
From 2026, Nanyang Technological University (NTU) in Singapore will start offering a Master of Science in Chinese Medicine to develop highly skilled postgraduates with advanced expertise in both the theoretical foundations and practical applications of Chinese medicine.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
ProSpecBio launches Activin-A recombinant protein for brain injury research
Israel-based ProSpecBio, an evolving biotech company dedicated to providing highly purified proteins to the global research community, has announced the launch of its latest product: CHO cell-derived recombinant Activin-A, now available for immediate delivery worldwide.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
PAHO publishes guide for designing AI instructions in public health
The Pan American Health Organization (PAHO) has launched a new guide providing practical advice on how to create Artificial Intelligence (AI) prompts that generate reliable, relevant, and culturally appropriate content across diverse contexts.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Prerna launches India's first MicroRNA based blood test for breast cancer screening
Precision RNA Biotech (Prerna), a healthcare startup from Hyderabad, India has announced the launch of Cantel, India's first microRNA-based blood test for breast cancer screening.
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Poly Medicure announces acquisition of Citieffe Group for Rs 324 Cr
India-based medtech firm Poly Medicure has announced signing of a definitive agreement to acquire 100 per cent stake in Medistream SA (Group) consisting of Citieffe SRL and its step-down subsidiaries in USA & Mexico, at an Enterprise Value of Rs 324 crore (EUR 31 million).
1 min
BioSpectrum Asia Nov 2025
BioSpectrum Asia
Sumitomo, Novo Nordisk to co-promote obesity drug Wegovy in Japan
Sumitomo Pharma and Novo Nordisk Pharma have entered into a co-promotion agreement in Japan for Wegovy Subcutaneous Injection, a once-weekly subcutaneous injection formulation of GLP-1 receptor agonist indicated for the treatment of obesity disease.
1 min
BioSpectrum Asia Nov 2025
Listen
Translate
Change font size
